Larimar Therapeutics, Inc. (LRMR) has released an update.
Larimar Therapeutics, Inc. successfully completed an underwritten public offering on February 14, 2024, issuing over 17 million shares at $8.74 each, and an additional option for underwriters was fully exercised, bringing total net proceeds to approximately $161.8 million. The offering, managed by Leerink Partners, Citigroup Global Markets, and Guggenheim Securities, closed on February 16, 2024, with all shares being sold by the company under an effective shelf registration statement.
For further insights into LRMR stock, check out TipRanks’ Stock Analysis page.
